Can-Fite BioPharma annual free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma Free Cash Flow (FCF) History (CANF)
Can-Fite BioPharma reported −$9.0M in free cash flow for fiscal 2025, a decrease of $1.3M from the previous fiscal year, with a free cash flow margin of −2210.12%.
View full Can-Fite BioPharma company overviewCan-Fite BioPharma free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$9.0M | −$1.3M | — | −2210.12% |
| 2024 | 2024-12-31 | −$7.6M | $800,000 | — | −1133.83% |
| 2023 | 2023-12-31 | −$8.4M | $2.4M | — | −1136.20% |
| 2022 | 2022-12-31 | −$10.8M | −$941,000 | — | −1334.57% |
| 2021 | 2021-12-31 | −$9.9M | $2.2M | — | −1156.98% |
| 2020 | 2020-12-31 | −$12.1M | −$1.0M | — | −1584.40% |
| 2019 | 2019-12-31 | −$11.1M | −$6.9M | — | −545.62% |
| 2018 | 2018-12-31 | −$4.2M | $4.8M | — | −109.63% |
| 2017 | 2017-12-31 | −$9.0M | −$255,000 | — | −1138.02% |
| 2016 | 2016-12-31 | −$8.7M | — | — | −5287.27% |
Can-Fite BioPharma quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Can-Fite BioPharma free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$12.1M to −$9.0M, a net increase of $3.1M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Can-Fite BioPharma filings at SEC.gov ↗